EPIMETRIC: A cfDNA Methylation-Based Algorithm for COPD Diagnosis and Stratification.

Area of Science:

• Genomics
• Epigenetics
• Biomarker Discovery

Background:

• Chronic Obstructive Pulmonary Disease (COPD) diagnosis and staging are critical for effective management.
• Current diagnostic methods can be invasive or lack precision in disease stratification.
• Cell-free DNA (cfDNA) methylation patterns hold potential as non-invasive biomarkers.

Purpose of the Study:

• To develop and validate a blood-based algorithm for COPD diagnosis.
• To stratify COPD patients according to the Global Initiative for Chronic Obstructive Lung Disease (GOLD) classification using cfDNA methylation.
• To identify novel cfDNA methylation signatures associated with COPD and its severity.

Main Methods:

• Genome-wide cfDNA methylation analysis was performed on 166 participants (80 COPD, 86 controls).
• A hierarchical support vector machine (SVM) classifier was trained to distinguish COPD from controls and stratify GOLD stages.
• Differential methylation analysis and functional enrichment analyses were conducted.

Main Results:

• A cfDNA methylation signature (EPIMETRIC) achieved complete separation between COPD patients and healthy controls.
• The EPIMETRIC classifier accurately distinguished GOLD A, B, and D COPD subgroups.
• Differential methylation analysis identified numerous genes and pathways linked to COPD and GOLD classification, including glutamatergic synapse and nicotine addiction.

Conclusions:

• EPIMETRIC is the first blood-based cfDNA methylation signature for COPD diagnosis and GOLD stratification.
• This minimally invasive test offers high accuracy for early detection and personalized treatment strategies.
• EPIMETRIC facilitates the identification of high-risk COPD patients.